AmnioFill is a minimally manipulated, non-viable cellular tissue matrix allograft that contains multiple extracellular matrix proteins, growth factors, cytokines, and other specialty proteins present in placental tissue to help enhance healing.
AmnioFill is intended for homologous use as a placental connective tissue matrix to replace or supplement damaged or inadequate integumental tissue for acute and chronic wounds and modulate inflammation, enhance healing and reduce scar tissue formation.
AmnioFill is processed from human tissue according to the American Association of Tissue Banks (AATB) standards, and is regulated as a human cell, tissue, or cellular or tissue-based product (HCT/P) under Section 361 of the Public Health Service Act.
